J. Holm et al., High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: Radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity, ARCH BIOCH, 366(2), 1999, pp. 183-191
High-affinity folate receptors are expressed in normal ovaries and ovarian
carcinomas. Binding of [H-3]folate in human ovary, serous ovarian carcinoma
tissue, and ascites is a complex process that has not been well characteri
zed. This study shows changes in binding affinity and mechanism of binding
with decreasing receptor concentration, inhibition by folate derivatives, a
nd a slow radioligand dissociation at pH 7.4 becoming rapid and complete at
pH 3.5, The receptor seems to be positively charged since it elutes in the
front effluent of a DEAE-Sepharose CL-6B ion-exchange column at pH 6.3, Th
e gel filtration profile of Triton X-100-solubilized tissue and ascites con
tained two peaks of radioligand-bound receptor (25 and 100 kDa), Exposure o
f ascites to cleavage by phosphati-dylinositol-specific phospholipase C res
ulted in a partial conversion of the 100-kDa peak to a 25-kDa peak. This su
ggests that the receptor may be anchored to the membrane by a glycosylphosp
hatidyl residue that inserts into Triton X-100 micelles, resulting in a lar
ge molecular size on gel filtration. The receptor in ovarian carcinoma tiss
ue immunoreacts with antibodies against purified human milk folate receptor
protein as shown by enzyme-linked immunosorbent assay, immunoprecipitation
, sodium dodecyl sulfate-polyacrylamide gel electrophoresis immunoblotting
(a single band of 45 kDa), and immunohistochemistry. In only three of seven
ovarian carcinomas did expression of radio-ligand-bound receptors exceed l
evels found in five normal ovaries, However, only receptors in ovarian carc
inoma specimens showed a high degree of immunoreactivity, Hence, even witho
ut elevations of the total receptor level, a folate receptor isoform homolo
gous to human milk folate receptor protein seemed to prevail in serous ovar
ian carcinomas. (C) 1999 Academic Press.